Literature DB >> 17507469

Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization.

Emilia Falkowska1, Francis Kajumo, Edie Garcia, John Reinus, Tatjana Dragic.   

Abstract

Hepatitis C virus (HCV) is a major human pathogen that causes serious liver disease, including cirrhosis and hepatocellular carcinoma. The primary target cells of HCV are hepatocytes, and entry is restricted by interactions of the envelope glycoproteins, E1 and E2, with cellular receptors. E1 and E2 form noncovalently linked heterodimers and are heavily glycosylated. Glycans contribute to protein folding and transport as well as protein function. In addition, glycans associated with viral envelopes mask important functional domains from the immune system and attenuate viral immunogenicity. Here, we explored the role of N- and O-linked glycans on E2, which is the receptor binding subunit of the HCV envelope. We identified a number of glycans that are critical for viral entry. Importantly, we showed that the removal of several glycans significantly increased the inhibition of entry by sera from HCV-positive individuals. Only some of the glycans that affected entry and neutralization were also important for CD81 binding. Our results show that HCV envelope-associated glycans play a crucial role in masking functionally important regions of E2 and suggest a new strategy for eliciting highly neutralizing antibodies against this virus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17507469      PMCID: PMC1951298          DOI: 10.1128/JVI.00459-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans.

Authors:  François Helle; Czeslaw Wychowski; Ngoc Vu-Dac; Kirk R Gustafson; Cécile Voisset; Jean Dubuisson
Journal:  J Biol Chem       Date:  2006-06-29       Impact factor: 5.157

2.  L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus.

Authors:  Jason P Gardner; Robert J Durso; Robert R Arrigale; Gerald P Donovan; Paul J Maddon; Tatjana Dragic; William C Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-03       Impact factor: 11.205

3.  Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class II fusion proteins.

Authors:  Robert F Garry; Srikanta Dash
Journal:  Virology       Date:  2003-03-15       Impact factor: 3.616

4.  DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2.

Authors:  Pierre-Yves Lozach; Hugues Lortat-Jacob; Agnès de Lacroix de Lavalette; Isabelle Staropoli; Steven Foung; Ali Amara; Corinne Houles; Frank Fieschi; Olivier Schwartz; Jean-Louis Virelizier; Fernando Arenzana-Seisdedos; Ralf Altmeyer
Journal:  J Biol Chem       Date:  2003-02-27       Impact factor: 5.157

5.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

Review 6.  Humoral immune response against hepatitis C virus.

Authors:  R Burioni; N Mancini; F Canducci; S Carletti; A Grieco; M Perotti; G Serafini; E Berardinelli; S Bighi; P E Varaldo; M Clementi
Journal:  J Biol Regul Homeost Agents       Date:  2003 Apr-Jun       Impact factor: 1.711

7.  Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.

Authors:  Birke Bartosch; Alessandra Vitelli; Christelle Granier; Caroline Goujon; Jean Dubuisson; Simona Pascale; Elisa Scarselli; Riccardo Cortese; Alfredo Nicosia; François-Loïc Cosset
Journal:  J Biol Chem       Date:  2003-08-11       Impact factor: 5.157

8.  Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR.

Authors:  Stefan Pöhlmann; Jie Zhang; Frédéric Baribaud; Zhiwei Chen; George J Leslie; George Lin; Angela Granelli-Piperno; Robert W Doms; Charles M Rice; Jane A McKeating
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.

Authors:  Birke Bartosch; Jens Bukh; Jean-Christophe Meunier; Christelle Granier; Ronald E Engle; William C Blackwelder; Suzanne U Emerson; François-Loïc Cosset; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-14       Impact factor: 11.205

10.  Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection.

Authors:  Vicky M-H Sung; Shigetaka Shimodaira; Alison L Doughty; Gaston R Picchio; Huong Can; T S Benedict Yen; Karen L Lindsay; Alexandra M Levine; Michael M C Lai
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more
  69 in total

1.  Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.

Authors:  Zhen-Yong Keck; Anasuya Saha; Jinming Xia; Yong Wang; Patrick Lau; Thomas Krey; Felix A Rey; Steven K H Foung
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

Review 2.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

3.  Interaction of human, rat, and mouse immunoglobulin A (IgA) with Staphylococcal superantigen-like 7 (SSL7) decoy protein and leukocyte IgA receptor.

Authors:  Bruce D Wines; Paul A Ramsland; Halina M Trist; Sandra Gardam; Robert Brink; John D Fraser; P Mark Hogarth
Journal:  J Biol Chem       Date:  2011-07-22       Impact factor: 5.157

4.  Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.

Authors:  Zhenyong Keck; Wenyan Wang; Yong Wang; Patrick Lau; Thomas H R Carlsen; Jannick Prentoe; Jinming Xia; Arvind H Patel; Jens Bukh; Steven K H Foung
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

5.  Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.

Authors:  Lisa N Wasilewski; Stuart C Ray; Justin R Bailey
Journal:  J Gen Virol       Date:  2016-09-21       Impact factor: 3.891

6.  Impact of Protein Glycosylation on the Design of Viral Vaccines.

Authors:  Kathleen Schön; Bernd Lepenies; Guillaume Goyette-Desjardins
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

7.  Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity.

Authors:  Emmanuel Fenouillet; Dimitri Lavillette; Silvia Loureiro; George Krashias; Guillemette Maurin; François-Loïc Cosset; Ian M Jones; Rym Barbouche
Journal:  J Biol Chem       Date:  2008-07-30       Impact factor: 5.157

8.  The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule.

Authors:  Thomas Krey; Jacques d'Alayer; Carlos M Kikuti; Aure Saulnier; Laurence Damier-Piolle; Isabelle Petitpas; Daniel X Johansson; Rajiv G Tawar; Bruno Baron; Bruno Robert; Patrick England; Mats A A Persson; Annette Martin; Félix A Rey
Journal:  PLoS Pathog       Date:  2010-02-19       Impact factor: 6.823

9.  Generation of infectious HCV pseudo typed particles and its utilization for studying the role of CD81 & SRBI receptors in HCV infection.

Authors:  Shazia Rafique; Muhammad Idrees; Amjad Ali; Kashif Iqbal Sahibzada; Muhammad Iqbal
Journal:  Mol Biol Rep       Date:  2014-02-19       Impact factor: 2.316

Review 10.  Hepatitis C Virus entry: the early steps in the viral replication cycle.

Authors:  Ali Sabahi
Journal:  Virol J       Date:  2009-07-30       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.